Propidium monoazide (PMA) with quantitative PCR to detect and quantify viable Paenibacillus larvae and Melissococcus plutonius in honeybee hive samples

preprint OA: closed
Full text JSON View at publisher
Full text 1,882 characters · extracted from oa-doi-fallback · click to expand
ABSTRACT Paenibacillus larvae and Melissococcus plutonius are the bacterial agents responsible for American and European foulbrood diseases, respectively, and pose significant economic threats to apiculture worldwide. Early detection of these pathogens is critical for effective disease prevention and management in honeybee colonies. P. larvae forms highly persistent spores that can remain infectious on hive equipment for decades, whereas the non-spore-forming M. plutonius can survive for over a year in contaminated materials. Although various decontamination and treatment strategies are available or under development, reliable methods for quantifying these pathogens are essential for accurately assessing their effectiveness. Culture-based techniques and quantitative PCR (qPCR) are commonly used to detect and quantify foulbrood pathogens in hive-associated samples; however, culturing is labor-intensive and sometimes inconsistent, while qPCR does not distinguish between viable and dead cells. Propidium monoazide (PMA) selectively binds DNA from dead cells and prevents its amplification during qPCR, enabling viable-cell quantification. Despite this advantage, the performance of PMA-qPCR for detecting P. larvae and M. plutonius in hive samples has not previously been assessed. In this study, we evaluated PMA-qPCR using both pure cultures and environmentally relevant honeycomb samples before and after ozone treatment. PMA treatment greatly reduced the erroneous detection of dead cells by several orders of magnitude in both culture and hive samples, supporting its utility for AFB and EFB risk assessment and treatment evaluation. However, incomplete suppression of dead-cell DNA at high cell densities indicates that further optimization of PMA treatment conditions may be necessary. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00